Charles Schwab Investment Management Inc Akebia Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 749,015 shares of AKBA stock, worth $1.66 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
749,015
Previous 622,914
20.24%
Holding current value
$1.66 Million
Previous $1.2 Million
128.12%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding AKBA
# of Institutions
174Shares Held
106MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$32.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$25.7 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$17.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$13.4 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.7 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $406M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...